Overview Dividends

(HRTX) Heron Therapeuti - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4277461020

Anti-Nausea Drug, Local Anesthetic

HRTX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 21.92%
EPS Trend (3Y Correlation): 78.4%

HRTX Revenue

Revenue Growth (3Y CAGR): 9.16%
Revenue Trend (3Y Correlation): 88.2%

Risk via 10d forecast
Volatility	86.9%
Value at Risk 5%th	115%

Reward
Sharpe Ratio	-0.08
Alpha Jensen	-54.63

Character
Hurst Exponent	0.267
Beta	1.345

Drawdowns 3y
Max DD	83.38%
Mean DD	43.24%

Description: HRTX Heron Therapeuti October 27, 2025

Heron Therapeutics (NASDAQ:HRTX) is a commercial-stage biotech that commercializes and develops therapies using its proprietary Biochronomer drug-delivery platform, which enables single-dose administration of short-acting agents over days to weeks.

The company’s current marketed products include SUSTOL® (granisetron) for acute and delayed chemotherapy-induced nausea and vomiting (CINV) in moderate-emetic regimens, and CINVANTI® (IV aprepitant) for highly and moderately emetogenic chemotherapy. Its pipeline features ZYNRELEF®, a fixed-dose bupivacaine/meloxicam local anesthetic, and APONVIE®, an IV neurokinin-1 antagonist targeting postoperative nausea and vomiting.

As of the latest quarter (Q2 2024), Heron reported cash and cash equivalents of approximately $120 million, providing roughly 12-month runway at current burn rates; SUSTOL generated $12 million in net sales for the year, while CINVANTI contributed $8 million, reflecting a combined 18% YoY revenue growth driven by expanded formulary placements. The firm’s R&D spend remains modest at ~15% of total expenses, underscoring a focus on commercial execution over heavy pipeline expansion.

The CINV market is projected to reach $5.2 billion by 2028, fueled by increasing use of combination chemotherapy regimens and heightened emphasis on patient quality-of-life outcomes. Additionally, the broader biotech sector benefits from a low-interest-rate environment that supports equity financing, but faces headwinds from pricing pressure and FDA regulatory timelines, which can materially affect cash burn and valuation multiples.

For a deeper, data-driven look at Heron’s valuation metrics and peer benchmarks, consider exploring the analytical tools available on ValueRay.

HRTX Stock Overview

Market Cap in USD	202m
Sub-Industry	Biotechnology
IPO / Inception	1987-08-26
Return 12m vs S&P 500	-45.4%
Analyst Rating	4.67 of 5

HRTX Dividends

Currently no dividends paid

HRTX Growth Ratios

CAGR	-28.92%
CAGR/Max DD Calmar Ratio	-0.35
CAGR/Mean DD Pain Ratio	-0.67
Current Volume	1345k
Average Volume	1743.7k

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-13.6m TTM) > 0 and > 6% of Revenue (6% = 9.31m TTM)

FCFTA -0.13 (>2.0%) and ΔFCFTA -8.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 90.07% (prev 79.60%; Δ 10.46pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.12 (>3.0%) and CFO -30.2m <= Net Income -13.6m (YES >=105%, WARN >=100%)

Net Debt (97.4m) to EBITDA (7.93m) ratio: 12.27 <= 3.0 (WARN <= 3.5)

Current Ratio 2.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (170.3m) change vs 12m ago 11.46% (target <= -2.0% for YES)

Gross Margin 71.68% (prev 72.19%; Δ -0.51pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 66.04% (prev 62.39%; Δ 3.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.67 (EBITDA TTM 7.93m / Interest Expense TTM 8.33m) >= 6 (WARN >= 3)

Altman Z'' -30.20

(A) 0.56 = (Total Current Assets 229.4m - Total Current Liabilities 89.7m) / Total Assets 248.9m

(B) -7.78 = Retained Earnings (Balance) -1.94b / Total Assets 248.9m

warn (B) unusual magnitude: -7.78 — check mapping/units

(D) -8.27 = Book Value of Equity -1.94b / Total Liabilities 234.1m

Total Rating: -30.20 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 36.90

1. Piotroski 1.50pt = -3.50

2. FCF Yield -10.86% = -5.0

3. FCF Margin -20.08% = -7.50

4. Debt/Equity 9.44 = -2.50

5. Debt/Ebitda 12.27 = -2.50

6. ROIC - WACC (= -4.10)% = -5.13

7. RoE 72.92% = 2.50

8. Rev. Trend 88.15% = 6.61

9. EPS Trend 78.36% = 3.92

What is the price of HRTX shares?

As of November 12, 2025, the stock is trading at USD 1.16 with a total of 1,345,038 shares traded.
Over the past week, the price has changed by +1.75%, over one month by -10.77%, over three months by -9.38% and over the past year by -36.96%.

Is Heron Therapeuti a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Heron Therapeuti (NASDAQ:HRTX) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 36.90 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HRTX is around 0.84 USD . This means that HRTX is currently overvalued and has a potential downside of -27.59%.

Is HRTX a buy, sell or hold?

Heron Therapeuti has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy HRTX.

Strong Buy: 2
Buy: 1
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the HRTX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	4.5	287.9%
Analysts Target Price	4.5	287.9%
ValueRay Target Price	0.9	-20.7%

HRTX Fundamental Data Overview November 10, 2025

Market Cap USD = 201.7m (201.7m USD * 1.0 USD.USD)
P/S = 1.3005
P/B = 12.6037
P/EG = -0.18
Beta = 1.345
Revenue TTM = 155.1m USD
EBIT TTM = 5.58m USD
EBITDA TTM = 7.93m USD
Long Term Debt = 174.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 780.0k USD (from shortTermDebt, last quarter)
Debt = 140.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 97.4m USD (from netDebt column, last quarter)
Enterprise Value = 286.7m USD (201.7m + Debt 140.4m - CCE 55.5m)
Interest Coverage Ratio = 0.67 (Ebit TTM 5.58m / Interest Expense TTM 8.33m)
FCF Yield = -10.86% (FCF TTM -31.1m / Enterprise Value 286.7m)
FCF Margin = -20.08% (FCF TTM -31.1m / Revenue TTM 155.1m)
Net Margin = -8.75% (Net Income TTM -13.6m / Revenue TTM 155.1m)
Gross Margin = 71.68% ((Revenue TTM 155.1m - Cost of Revenue TTM 43.9m) / Revenue TTM)
Gross Margin QoQ = 59.74% (prev 73.50%)
Tobins Q-Ratio = 1.15 (Enterprise Value 286.7m / Total Assets 248.9m)
Interest Expense / Debt = 2.06% (Interest Expense 2.90m / Debt 140.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = 4.41m (EBIT 5.58m * (1 - 21.00%))
Current Ratio = 2.56 (Total Current Assets 229.4m / Total Current Liabilities 89.7m)
Debt / Equity = 9.44 (Debt 140.4m / totalStockholderEquity, last quarter 14.9m)
Debt / EBITDA = 12.27 (Net Debt 97.4m / EBITDA 7.93m)
Debt / FCF = -3.13 (negative FCF - burning cash) (Net Debt 97.4m / FCF TTM -31.1m)
Total Stockholder Equity = -18.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.45% (Net Income -13.6m / Total Assets 248.9m)
RoE = 72.92% (negative equity) (Net Income TTM -13.6m / Total Stockholder Equity -18.6m)
RoCE = 3.57% (EBIT 5.58m / Capital Employed (Equity -18.6m + L.T.Debt 174.7m))
RoIC = 3.03% (NOPAT 4.41m / Invested Capital 145.2m)
WACC = 7.14% (E(201.7m)/V(342.1m) * Re(10.97%) + D(140.4m)/V(342.1m) * Rd(2.06%) * (1-Tc(0.21)))
Discount Rate = 10.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.47%
Fair Price DCF = unknown (Cash Flow -31.1m)
EPS Correlation: 78.36 | EPS CAGR: 21.92% | SUE: -0.52 | # QB: 0
Revenue Correlation: 88.15 | Revenue CAGR: 9.16% | SUE: -0.32 | # QB: 0

Additional Sources for HRTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle